FDA Lifts Clinical Hold on Lpath’s iSONEP

Lpath reported that the FDA has lifted the clinical hold on iSONEP, Lpath’s anti-S1P monoclonal antibody that is being developed as a potential treatment for wet AMD and possibly other ocular disorders.
Yahoo! Finance